Ocular Therapeutix (OCUL) news
Recent news
Rival Ocular Therapeutix shares up 8%
Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares rose approximately 8% in afternoon trading on August 17, 2026, following the company’s announcement of a regulatory milestone. The biopharmaceutical firm disclosed that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the…
AInvest Wire · Aug 17, 2026Ocular Therapeutix shares up 12.7% premarket after rival Eyepoint's eye drug misses main goal in late-stage trial
AInvest Wire · Aug 17, 2026Ocular Therapeutix Q2 product revenue USD 13.48 million
Ocular Therapeutix reported product revenue of $13.48 million for the second quarter of 2025, according to recent financial disclosures. This figure reflects a slight decline compared to the same period in the prior year, when the company generated $16.44 million in revenue. The current quarter’s…
AInvest Wire · Aug 3, 2026Ocular Therapeutix 2Q revenue $13.5M, estimate $13.2M
AInvest Wire · Aug 3, 2026Ocular Therapeutix, Inc.: H.C. Wainwright raises target price to $25 from $21
H.C. Wainwright & Co. has revised its price target for Ocular Therapeutix, Inc. (OCUL), raising it to $25 from $21, reflecting a positive reassessment of the company’s outlook. The updated target suggests increased confidence in the firm’s potential performance, though it does not indicate a change…
AInvest Wire · Jun 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.